Advancing Precision Lung Cancer Surveillance and Outcomes in Diverse Populations
This observational study evaluates the effectiveness of computed tomography (CT) imaging surveillance after curative-intent treatment for stage I-IIIA non-small cell lung cancer (NSCLC) in a diverse U.S. population. The main questions are: How do CT surveillance use and adherence vary by race, ethnicity, and socioeconomic status? Does semi-annual CT surveillance improve outcomes compared with annual surveillance? Adults ages 20-90 with stage I-IIIA NSCLC treated between 2012 and 2026 will be identified using OneFlorida+ electronic health records, tumor registry data, claims, and clinical notes. Patients will be followed for up to five years after curative-intent therapy to evaluate surveillance patterns, recurrence, second primary lung cancers, complications, and survival.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated May 12, 2026 · Source: ClinicalTrials.gov
The study is underway but is not accepting new participants.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- University of Florida
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Adults diagnosed with primary, pathologically confirmed stage I-IIIA non- small cell lung cancer (NSCLC).
- Received curative-intent therapy, including: Surgical resection, or Stereotactic body radiation therapy (SBRT), with or without adjuvant therapy.
- Completed curative-intent therapy and survived at least 5 months after therapy initiation.
- Received care within the University of Florida (Gainesville or Jacksonville) health system, and are included in the OneFlorida+ clinical data network.
- Have available: Structured EHR data (including tumor registry linkage, imaging, procedures, and vital statistics), and Unstructured clinical documents (clinic notes, radiology reports, pathology reports) enable NLP extraction. \- Have ≥1 follow-up encounter in the EHR after treatment completion to allow surveillance assessment.
- Histology other than NSCLC, including: Small-cell lung cancer Carcinoid tumors Rare non-NSCLC primary tumors
- Metastatic disease (stage IV) at diagnosis.
- No curative-intent therapy received (e.g., palliative treatment only).
- Patients with incomplete treatment records prevent the determination of the treatment completion date.
- Patients with no surveillance-relevant follow-up data, including: No post-treatment clinical notes No radiology/pathology records No linked tumor registry or vital status data
- Patients with recurrence or who die within the first 5 months after starting curative-intent therapy (insufficient window for guideline-defined surveillance).
- Patients with missing identifiers prevent linkage to cancer registries or the death index.
- Individuals whose imaging cannot be classified as surveillance vs. diagnostic due to the absence of relevant structured or unstructured data.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Florida College of MedicineGainesville, Florida
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 12, 2026. Always confirm current availability with the study team.